Abstract
Purpose: Tumors with p53 overexpression have been associated with enhanced resistance to cisplatin-based chemotherapy in a few and small studies involving non-small cell lung cancer. The relationships and interactions between p53, Rb and bcl-2 immunostaining, clinical parameters and response to cisplatin-based chemotherapy were evaluated in the present study. Experimental design: Histological specimens obtained by bronchial or fine-needle biopsy from patients who underwent cisplatin-based chemotherapy between 1992 and 1999 were evaluated by immunostaining. Results: There were 102 patients, 88 men. Median age was 63 years; 47 had stage III and 55 stage IV disease. Forty-six tumor samples (45%) had positive immunostaining for p53, 61 (59%) had negative immunostaining for Rb and 8 (8%) had positive immunostaining for bcl-2. The response rate of the group with p53 positive immunostaining was 26% versus 57% of the p53 negative group (P=0.004). In multivariate analyses p53 positive immunostaining was identified as an independent predictive factor for resistance to cisplatin-based chemotherapy (P=0.006). Conclusions: Our study confirmed an association of p53 immunostaining and response rate of patients treated with cisplatin-based chemotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 41-48 |
| Number of pages | 8 |
| Journal | Lung Cancer |
| Volume | 39 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 1 2003 |
Fingerprint
Keywords
- bcl-2
- Chemotherapy
- Cisplatin
- Lung cancer
- p53
- Resistance
- Retinoblastoma
ASJC Scopus subject areas
- Oncology
Cite this
Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer. / Gregorc, Vanesa; Ludovini, Vienna; Pistola, Lorenza; Darwish, Samir; Floriani, Irene; Bellezza, Guido; Sidoni, Angelo; Cavaliere, Antonio; Scheibel, Massimo; De Angelis, Verena; Bucciarelli, Emilio; Tonato, Maurizio.
In: Lung Cancer, Vol. 39, No. 1, 01.01.2003, p. 41-48.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer
AU - Gregorc, Vanesa
AU - Ludovini, Vienna
AU - Pistola, Lorenza
AU - Darwish, Samir
AU - Floriani, Irene
AU - Bellezza, Guido
AU - Sidoni, Angelo
AU - Cavaliere, Antonio
AU - Scheibel, Massimo
AU - De Angelis, Verena
AU - Bucciarelli, Emilio
AU - Tonato, Maurizio
PY - 2003/1/1
Y1 - 2003/1/1
N2 - Purpose: Tumors with p53 overexpression have been associated with enhanced resistance to cisplatin-based chemotherapy in a few and small studies involving non-small cell lung cancer. The relationships and interactions between p53, Rb and bcl-2 immunostaining, clinical parameters and response to cisplatin-based chemotherapy were evaluated in the present study. Experimental design: Histological specimens obtained by bronchial or fine-needle biopsy from patients who underwent cisplatin-based chemotherapy between 1992 and 1999 were evaluated by immunostaining. Results: There were 102 patients, 88 men. Median age was 63 years; 47 had stage III and 55 stage IV disease. Forty-six tumor samples (45%) had positive immunostaining for p53, 61 (59%) had negative immunostaining for Rb and 8 (8%) had positive immunostaining for bcl-2. The response rate of the group with p53 positive immunostaining was 26% versus 57% of the p53 negative group (P=0.004). In multivariate analyses p53 positive immunostaining was identified as an independent predictive factor for resistance to cisplatin-based chemotherapy (P=0.006). Conclusions: Our study confirmed an association of p53 immunostaining and response rate of patients treated with cisplatin-based chemotherapy.
AB - Purpose: Tumors with p53 overexpression have been associated with enhanced resistance to cisplatin-based chemotherapy in a few and small studies involving non-small cell lung cancer. The relationships and interactions between p53, Rb and bcl-2 immunostaining, clinical parameters and response to cisplatin-based chemotherapy were evaluated in the present study. Experimental design: Histological specimens obtained by bronchial or fine-needle biopsy from patients who underwent cisplatin-based chemotherapy between 1992 and 1999 were evaluated by immunostaining. Results: There were 102 patients, 88 men. Median age was 63 years; 47 had stage III and 55 stage IV disease. Forty-six tumor samples (45%) had positive immunostaining for p53, 61 (59%) had negative immunostaining for Rb and 8 (8%) had positive immunostaining for bcl-2. The response rate of the group with p53 positive immunostaining was 26% versus 57% of the p53 negative group (P=0.004). In multivariate analyses p53 positive immunostaining was identified as an independent predictive factor for resistance to cisplatin-based chemotherapy (P=0.006). Conclusions: Our study confirmed an association of p53 immunostaining and response rate of patients treated with cisplatin-based chemotherapy.
KW - bcl-2
KW - Chemotherapy
KW - Cisplatin
KW - Lung cancer
KW - p53
KW - Resistance
KW - Retinoblastoma
UR - http://www.scopus.com/inward/record.url?scp=0037215619&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037215619&partnerID=8YFLogxK
U2 - 10.1016/S0169-5002(02)00391-4
DO - 10.1016/S0169-5002(02)00391-4
M3 - Article
C2 - 12499093
AN - SCOPUS:0037215619
VL - 39
SP - 41
EP - 48
JO - Lung Cancer
JF - Lung Cancer
SN - 0169-5002
IS - 1
ER -